Last week, the pharmaceutical giant Insys Therapeutics scored a major victory when it was announced that their new synthetic THC drug – Syndros – was approved by the Drug Enforcement Administration for placement on Schedule II of the federal Controlled Substances Act. According to Dr. Santosh Vetticaden, Ph.D., M.D., Interim CEO, and Chief Medical Officer … Continue reading Anti-Legalization Pharmaceutical Company Gets Schedule II Clearance for its Synthetic THC Drug